New personalized chemo approach aims to boost survival in aggressive breast cancer

NCT ID NCT02810743

First seen Jan 11, 2026 · Last updated Apr 25, 2026 · Updated 16 times

Summary

This study tests whether a personalized, high-dose chemotherapy regimen with stem cell rescue can improve survival for people with high-risk, BRCA1-like breast cancer. The trial includes 174 participants with stage III, HER2-negative breast cancer. The goal is to see if this tailored approach works better than standard chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AZVU

    Amsterdam, 1081 HV, Netherlands

  • Antoni van Leeuwenhoek

    Amsterdam, 1066 CX, Netherlands

  • Erasmus Medical Center Cancer Institute

    Rotterdam, 3015CE, Netherlands

  • Hopital Tenon, University Marie-Curie

    Paris, France

  • Institut Paoli Calmettes

    Marseille, 13009, France

  • LUMC

    Leiden, 2333 ZA, Netherlands

  • Maastricht University Medical Center

    Maastricht, Netherlands

  • Medical spectrum Twente

    Enschede, Overijssel, 7500 KA, Netherlands

  • Radboud UMC

    Nijmegen, 6225GA, Netherlands

  • University Medical Center Groningen

    Groningen, Netherlands

  • University Medical Center Utrecht

    Utrecht, 3584CX, Netherlands

Conditions

Explore the condition pages connected to this study.